KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other financing activities: 2013-2023

Historic Other financing activities for Travere Therapeutics (TVTX) over the last 3 years, with Dec 2023 value amounting to -$259,000.

  • Travere Therapeutics' Other financing activities was N/A to -$259,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.4 million, marking a year-over-year change of. This contributed to the annual value of -$1.4 million for FY2023, which is 113.99% down from last year.
  • Travere Therapeutics' Other financing activities amounted to -$259,000 in Q4 2023, which was up 0.38% from -$260,000 recorded in Q3 2023.
  • In the past 5 years, Travere Therapeutics' Other financing activities registered a high of $9.5 million during Q1 2022, and its lowest value of -$6.1 million during Q4 2021.
  • Its 3-year average for Other financing activities is $342,286, with a median of -$259,000 in 2023.
  • Data for Travere Therapeutics' Other financing activities shows a maximum YoY slumped of 165.74% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Travere Therapeutics' Other financing activities stood at $772,000 in 2019, then reached -$6.1 million in 2021, then reached $394,000 in 2022, then crashed by 165.74% to -$259,000 in 2023.
  • Its Other financing activities was -$259,000 in Q4 2023, compared to -$260,000 in Q3 2023 and -$259,000 in Q2 2023.